Nivolumab plus cabozantinib (NIVO+CABO) showed significant benefits over sunitinib (SUN) in progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) for previously untreated advanced renal cell carcinoma (RCC) in the phase III CheckMate 9ER trial (NCT03141177). We report final, updated efficacy and safety results with median follow-up of 5.6 years.
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial☆
Annals of Oncology | | R.J. Motzer, B. Escudier, M. Burotto, T. Powles, A.B. Apolo, M.T. Bourlon, A.Y. Shah, C. Porta, C. Suárez, C.H. Barrios, M. Richardet, H. Gurney, E.R. Kessler, Y. Tomita, J. Bedke, C. Scheffold, M. Askelson, J. Panzica, J. Zhang, M. van Kooten Losio, T.K. Choueiri
Topics: blood-cancer, kidney-cancer, cervical-cancer, immunotherapy, clinical-trials